Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
6.80
+0.54 (8.63%)
Sep 17, 2025, 4:00 PM EDT - Market closed
Biodexa Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
4.21M USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 381.00K | -318.00K | -45.49% |
| Dec 31, 2022 | 699.00K | 121.00K | 20.93% |
| Dec 31, 2021 | 578.00K | 235.00K | 68.51% |
| Dec 31, 2020 | 343.00K | -331.00K | -49.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BDRX News
- 5 days ago - Interim results for the six months ended June 30, 2025 - GlobeNewsWire
- 9 days ago - Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled - Accesswire
- 4 weeks ago - Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewsWire
- 6 weeks ago - ADR Ratio Change Effective - GlobeNewsWire
- 7 weeks ago - How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market - Accesswire
- 2 months ago - ADR Ratio Change - GlobeNewsWire
- 2 months ago - Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewsWire
- 2 months ago - Results of Annual General Meeting - GlobeNewsWire